[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577884":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":36,"centralContacts":44,"locations":50,"responsibleParty":90,"collaborators":27,"id":94,"slug":27,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":27,"eligibilityCriteria":99,"healthyVolunteers":95,"sex":100,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":27,"studyType":106,"phases":107,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":53,"whyStopped":27,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Beximco Pharmaceuticals Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1","EXPERIMENTAL","Arm 1: Tab. Faropenem 200mg three times daily with standard care.",[13],"Drug: Faropenem",{"label":15,"type":16,"description":17,"interventionNames":18},"Arm 2","ACTIVE_COMPARATOR","Arm 2: Tab. Co-Amoxiclav 625mg three times daily and Tab. Clarithromycin 500mg two times daily with standard care.",[19,20],"Drug: Co-amoxiclav","Drug: Clarithromycin 500 mg",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Faropenem","Tab. Faropenem 200mg three times daily",[9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Co-amoxiclav","Tab. Co-Amoxiclav 625mg three times daily",[15],{"type":23,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"Clarithromycin 500 mg","Tab. Clarithromycin 500mg two times daily",[15],[37,41],{"name":38,"affiliation":39,"role":40},"Prof. Khan Abul Kalam Azad","Popular Medical College Hospital","PRINCIPAL_INVESTIGATOR",{"name":42,"affiliation":39,"role":43},"Prof. Quazi Tarikul Islam, MBBS, FCPS, FACP (USA), FRCP,","STUDY_DIRECTOR",[45],{"name":46,"role":47,"phone":48,"phoneExt":27,"email":49},"Prof. Khan Abul Kalam Azad, MBBS, FCPS, MD(Med), FACP(USA)","CONTACT","+880-1727271414","prof.kakazad@gmail.com",[51,79],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Popular Medical College & Hospital","RECRUITING","Dhaka","Dhaka Division","1205","Bangladesh",{"type":59,"coordinates":60},"Point",[61,62],90.40744,23.7104,{"lat":62,"lon":61},[65,67,70,72,74,76,78],{"name":66,"role":47,"phone":48,"phoneExt":27,"email":49},"Prof. Khan Abul Kalam Azad, FCPS(Med), MD (Med), FACP(USA)",{"name":68,"role":69,"phone":27,"phoneExt":27,"email":27},"Prof. Quazi Tarikul Islam, FCPS (Med), FACP (USA), FRCP","SUB_INVESTIGATOR",{"name":71,"role":69,"phone":27,"phoneExt":27,"email":27},"Prof. H.A.M. Nazmul Ahasan, MBBS, FCPS, FRCP",{"name":73,"role":69,"phone":27,"phoneExt":27,"email":27},"Prof. Md. Mujibur Rahman, MBBS, FCPS, MD, FACP (USA)",{"name":75,"role":69,"phone":27,"phoneExt":27,"email":27},"Prof. Mohammed Zahir Uddin, MBBS, FCPS, MD, FACP (USA)",{"name":77,"role":69,"phone":27,"phoneExt":27,"email":27},"Prof. Syed Ghulam Mogni Mowla, MBBS, FCPS, FRCPE, FACP (USA)",{"name":66,"role":40,"phone":27,"phoneExt":27,"email":27},{"facility":80,"status":53,"city":54,"state":55,"zip":56,"country":57,"cosmosGeoPoint":81,"geoPoint":83,"contacts":84},"Shaheed Suhrawardy Medical College & Hospital",{"type":59,"coordinates":82},[61,62],{"lat":62,"lon":61},[85,89],{"name":86,"role":47,"phone":87,"phoneExt":27,"email":88},"Prof. Mohammad Rafiqul Islam, MBBS(DU), FCPS, FACP . FRCP","+880-1753199796","drrafiq73@yahoo.com",{"name":86,"role":69,"phone":27,"phoneExt":27,"email":27},{"type":91,"investigatorFullName":92,"investigatorTitle":93,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"SPONSOR_INVESTIGATOR","Dr. Md. Alimur Reza","Director","100577884",false,"NCT06804096","Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)","Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP): A Randomized Controlled Trial","Inclusion Criteria:\n\n* Male or female patients aged between 18 to 65 years.\n* Have an acute illness (less than or equal to 7 days duration) with any of the following signs and symptoms consistent with a lower respiratory tract infection (new or worsening):\n\n  1. Fever (body temperature \\> 38.0 °C (100.4 °F) measured orally)\n  2. Shortness of breath\n  3. New onset or increased cough with or without sputum production.\n  4. Chest pain.\n* Have radiographically documented bacterial pneumonia:\n\n  1. Infiltrates in a unilateral, lobar distribution\n  2. Diffuse opacities or white condensed area\n  3. The alveoli fill with white inflammatory fluid\n\nExclusion Criteria:\n\n* Patients with severe pneumonia (Clinical \\& Radiological Assessment)\n* Patients with suspicion of viral pneumonia (bilateral, patchy opacities, etc., in chest radiography.)\n* Patients with suspicion of nosocomial pneumonia, aspiration pneumonia, etc.\n* History of hypersensitivity, known or suspected contraindications, or intolerance to any of the study drugs.\n* Intake of an antibiotic within the last 48 hours before study admission.\n* History of hospitalization within the last 28 days.\n* Patients in pregnancy and lactational state.\n* Patients with Renal impairment (screening eGFR \\\u003C 30mL\u002Fmin).\n* Significant hepatic impairment (Alanine aminotransferase \\> three times the upper limit of normal).\n* Serious diseases that affect the immune system, such as Acquired Immunodeficiency Syndrome (AIDS), cancer, etc.\n* Patients who are taking steroid medications, at least 20 mg daily dose of prednisolone (or equivalent doses of other glucocorticoids).\n* Patients who are accepting chemotherapy or anti-cancer therapy or plan to receive such treatment during the trial or six months prior to enrollment.\n* Had epilepsy, stroke, or other central nervous system disorders or uncontrolled psychiatric history.","ALL","18 Years","65 Years",{"count":104,"type":105},160,"ESTIMATED","INTERVENTIONAL",[108],"PHASE4","The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP). Eligible participants will be randomly assigned to one of two treatment arms. The first arm will receive faropenem at a dosage of 200 mg administered three times daily for a duration of seven days. The second arm will receive co-amoxiclav 625 mg, also three times daily, along with clarithromycin 500 mg, administered twice daily for seven days. All participants included in the study will undergo follow-up assessments over a period of four weeks. This research aims to provide valuable insights regarding the potential role of faropenem, thereby enhancing clinical outcomes and informing antibiotic stewardship in a region significantly burdened by CABP and characterized by limited treatment alternatives.",[111,112],"Pneumonia, Community-Acquired","Bacterial Pneumonia",[114,24],"CABP","2025-07-09",{"date":117,"type":118},"2025-07-11","ACTUAL",{"date":120,"type":118},"2025-02-20",{"date":122,"type":105},"2025-12-01",{"name":92,"class":6},2]